Virtual Library
Start Your Search
A. Šajnić
Moderator of
-
+
PA04 - Focus on Advocacy and Communication: Joint IASLC/ Global Lung Cancer Coalition Session (GLCC) (ID 358)
- Event: WCLC 2016
- Type: Patient & Advocacy Session
- Track: Patient Support and Advocacy Groups
- Presentations: 4
- Moderators:A. McNamara, A. Šajnić
- Coordinates: 12/06/2016, 14:30 - 15:45, Schubert 6
-
+
PA04.01 - A Realistic Goal? Achieving a Tobacco Free Ireland by 2025 (ID 6750)
14:30 - 14:45 | Author(s): D. Buggy
- Abstract
- Presentation
Abstract:
Introduction Ireland has a proud record of leadership in the field of tobacco control. It was the first country in the world to introduce a Workplace Smoking Ban in 2013 and the first country in Europe to announce its intention to introduce plain packaging for cigarettes. In 2013 Ireland set a target date to achieve a tobacco free society with a targeted adult tobacco use prevalence of under 5%. Other countries to formally adopt a target for tobacco free societies include Finland 2040, New Zealand 2025, and Scotland 2034. Tobacco Free Ireland[1] is a new tobacco policy for Ireland coming more than a decade after the publication of the previous national policy Towards a Tobacco Free Society[2]. It is a timely successor because of the emerging non-communicable disease burden which is caused by risk factors that can be prevented. Tobacco is well known as a major contributor to ill-health and premature mortality. It is responsible for more than a third of all cancers. For the first time, we have a target date for Ireland to be tobacco free of 2025. The question is whether this target is in any way realistic. Discussion Tobacco Free Ireland addresses a range of tobacco control issues and initiatives and contains over 60 recommendations. A high level action plan, was drawn up in consultation with those who will lead out on the recommendations which outlines the responsibilities, actions necessary and timelines for the implementation of the recommendations. The recommendations to support Ireland becoming a tobacco free Society are categorised under:- • Protection of children and denormalisation of tobacco use • Legislative compliance and regulating the retail environment • Protect people from tobacco use • Offer help to quit tobacco use • Warn about the dangers of tobacco • Enforcement of bans on tobacco advertising, promotion and sponsorship • Raising taxation on tobacco products • National and International Partnerships For the first time in policy we see a commitment to substantially address supply side issues through introduction of levies such as an environmental waste levy and an industry profitability levy ring fencing income to address health promotion, cessation supports and illegal trade initiatives. The document fails to substantially address the inequality inherent in smoking patterns. In Ireland the bottom decile, at 35% prevalence, is more than twice as likely to smoke as the top decile at 16%. Specific deprived population targeted programmes such as the Irish Cancer Societies ‘We Can Quit’ programme, which challenges intergenerational smoking, have been successful and need to be funded and enhanced if a Tobacco Free Society is to be achieved. Conclusion Current adult smoking rates of 19.5%[3] suggest Ireland has some significant way to go towards achieving its target. Recent youth smoking rates of 13%[4 ]for 15-17 year olds and 8%[5] for 10-17 year olds suggests significant progress in reducing the uptake of smoking. Major investment is required to support increased quit attempts and increased success from quit attempts if the target of a Tobacco Free Ireland by 2025 is to be achieved. References 1. http://health.gov.ie/wp-content/uploads/2014/03/TobaccoFreeIreland.pdf 2. http://health.gov.ie/blog/publications/towards-a-tobacco-free-society-report-of-the-tobacco-free-policy-review-group 3. http://health.gov.ie/wp-content/uploads/2015/10/Healthy-Ireland-Survey-2015-Summary-of-Findings.pdf 4. http://health.gov.ie/blog/publications/irelands-report-on-the-european-schools-project-on-alcohol-other-drugs-in-ireland-espad/ 5. http://health.gov.ie/wp-content/uploads/2016/01/HBSC2014web3.pdf
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
PA04.02 - The Global State of Lung Cancer Research – Communicating the Messages (ID 6751)
14:45 - 15:05 | Author(s): S. Winstone
- Abstract
- Presentation
Abstract:
Background: The Global Lung Cancer Coalition (GLCC) is a unique partnership, dedicated to improving disease outcomes for all lung cancer patients worldwide. Research is essential to drive improvements in cancer prevention, screening, diagnosis and treatment.[i] However, it is clear that lung cancer research is not being prioritised to a level that reflects its significant impact, with 1.8 million new cases globally every year.[ii] Poor lung cancer survival demonstrates that more can and should be done. The GLCC is calling for every country across the globe to examine and increase its investment in lung cancer research. Evidence of variations between countries in their approach to lung cancer research can be a powerful tool to advocate for increased investment and national policy that encourages a flourishing lung cancer research community. The GLCC commissioned the Institute of Cancer Policy at King’s College London to undertake a comprehensive examination of the state of global lung cancer research. The findings, published in the Journal of Thoracic Oncology, are intended to guide public policy and highlight where improvements can and should be made.[iii ]They have also been made available on the GLCC website with a range of campaigning materials for advocates to use in sharing insights and recommendations. Methodology: The GLCC commissioned the Institute of Cancer Policy at King’s College London to undertake a bibliometric review of global lung cancer research efforts. The team developed a complex validated mathematical algorithm to search articles and reviews in the Web of Science database for lung cancer research during 2004-13, looking to: · Identify the total number of papers in cancer research for each year in 24 leading countries, compared to that of other common cancers (breast and colorectal) · Isolate the number of papers referencing lung cancer or other relevant key words in their title The study identified the 24 countries globally with the most extensive research programmes in lung cancer. The authors’ research institutes were used to identify which country or countries had contributed to that paper. The study also analysed whether research outputs had changed over time as well as the focus of the research and how close the research is to patients. The methodology allows total number of papers, type, and research collaborations to be analysed over time. Results: The bibliometric review is a comprehensive and powerful resource allowing lung cancer patients, clinicians and policymakers to examine their national lung cancer research output and compare it with that of other countries. The 24 countries responsible for the majority of lung cancer research activity are: Australia, Austria, Belgium, Brazil, Canada, China (People’s Republic of), Denmark, France, Germany, Greece, India, Italy, Japan, Netherlands, Norway, Poland, Taiwan, Turkey, South Korea, Spain, Sweden, Switzerland, United Kingdom, and the USA (figure 1). Figure 1 Worldwide, the number of papers published on lung cancer has more than doubled from 2,157 papers in 2004 to 4,845 in 2013. However, there has only been a small increase in the proportion of global cancer research that is dedicated to lung cancer – from 4.4% in 2004 to 5.6% in 2013. By comparison (figure 2), both breast and colorectal cancer account for greater proportion of research activity, despite having a similar burden of disease. Figure 2 Colorectal cancer accounted for 6.2% of research activity in 2013 whereas breast cancer, at 10%, had nearly double the percentage of research activity compared to lung cancer. The figures can be used to make a persuasive case for increased investment in lung cancer research. To support this, the project team produced a campaigning toolkit, giving headline figures and statistics, tips for engagement and template briefings and press releases. Global and national-level briefing documents and infographics are also available on the GLCC’s website at: http://www.lungcancercoalition.org/en/state-global-lung-cancer-research. The GLCC is calling for every country across the globe to increase its investment in lung cancer research, to increase research efforts in aspects of care that are currently under-researched, and to collaborate with international partners to share findings and improve patient care. Conclusions: Feedback from GLCC members confirms that the bibliometric review is a valuable campaigning resource. The GLCC is keen for the review’s findings to be shared and for policymakers – nationally, regionally and globally – to consider how lung cancer research can be further supported. [i ]Yarden Y, Carols C, on behalf of the European Association for Cancer Research, Basic cancer research: why it is essential for the future of cancer therapy. European Journal of Cancer 2013, 49 issue 12. Accessed June 2015 [ii ]GLOBOCAN 2012, Lung Cancer, available here: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed June 2015 [iii ]Aggarwal A, Lewison G, Idir S, et al. The State of Lung Cancer Research: A Global Analysis; J Thorac Oncol. 2016 Jul;11(7):1040-50
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
PA04.03 - Helpline: Adapting to Changing Needs and Evolving Science (ID 6752)
15:05 - 15:25 | Author(s): J.C. King
- Abstract
- Presentation
Abstract:
Helpline: Adapting to changing needs and evolving science The Lung Cancer Alliance HelpLine launched over 21 years ago and until recently was the only lung cancer-specific toll-free line in the United States. The reasons people call—for information, understanding, referral, compassion and most of all, hope—remain the same over time. But to keep pace with dramatic advances in the ways lung cancer is detected, diagnosed and treated, the LCA HelpLine has adapted quickly to meet the changing needs of our community. For many survivors and their loved ones, understanding lung cancer and its treatment is a challenge. Those impacted by the disease tend to be older, poorer and less educated, groups which also prefer to get their initial cancer information from their treatment teams. With competing time demands, treatment teams may not have enough time to ensure information is understood or to be sensitive to providing it when the survivor can absorb, process and remember. Some are hesitant to admit they don’t understand all they have been told and are uncomfortable asking questions. Over the past 3.5 years, there have been nearly equal numbers of patients and caregivers calling the HelpLine. Roughly three-quarters of callers were women. In 2016, LCA began tracking more call statistics. Of those who told us the type of lung cancer, we see 83% NSLCC and 17% SCLC – quite representative of the lung cancer population. More than half (53%) were already in treatment. As the science has evolved and practice-changing discoveries are made, professional HelpLine staff provide up-to-date information, support and referrals to those in our community, no matter their place in the journey. The HelpLine provides the opportunity for in-depth conversations, problem solving and the development of questions to ask the team—it serves not as a substitute for conversations with treatment team but as support and complement to them. The LCA HelpLine also has grown with the internet. For some, the internet is a wealth of knowledge, psychosocial support and information. But sometimes even savvy users need help interpreting the information they have found. For others, the internet is a scary and overwhelming place, full of difficult statistics, conflicting recommendations and hard to understand concepts. Additionally, many in our community do not have access to the internet at all or lack broadband speeds that make it an effective tool. While the internet can be helpful, it does not take the place of contact with another caring person who can help. The HelpLine also gives us daily contact with lung cancer community and allows us to keep abreast of what lung cancer patients, their loved ones and those at risk need most. And as we listen, we adapt our services and programs to their needs. For example, we have recently started offering a new webinar series on the top symptoms and side effects reported by those in treatment and long-term survivors. Recently, the pace of scientific discovery and drug development in lung cancer has been accelerating rapidly. With six new drugs approved by the Food and Drug Administration in 2015 and countless new clinical trials launching to test not only new drugs but novel combinations of different classes of agents, patients and caregivers can be even more confused about the best treatment options for them. To address this changing environment, we have recently launched the LungMatch program to help patients find and understand personalized treatment options that they can discuss with their treatment team. LungMatch includes referrals to a concierge service for molecular testing if patients have not had it, a new, user-friendly online matching platform, and in-house personalized clinical trial navigation for interested callers on the HelpLine. The program is still in its infancy, but in the first month of tracking, we determined that 85% of callers asked had never been on clinical trials and only 50% reported molecular testing of the lung cancer. These early statistics indicate the widespread need in the lung cancer community. Through adapting to the changing needs of our community and helping them understand the evolving science, the HelpLine has been a lifeline for the lung cancer community in the United States for over 21 years.
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
PA04.04 - How it Feels Campaign: The Impact of a Large General Public Campaign (ID 6753)
15:25 - 15:45 | Author(s): K. Bayne
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
